IPODIC ACID

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H13I3N2O2
Molecular Weight	597.9572
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C=NC1=C(I)C(CCC(O)=O)=C(I)C=C1I

InChI

InChIKey=YQNFBOJPTAXAKV-UHFFFAOYSA-N

InChI=1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C12H13I3N2O2
Molecular Weight	597.9572
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7608275 | https://www.ncbi.nlm.nih.gov/pubmed/3928675

Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperthyroidism 13 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7608275	Primary		Approved 8429	ORAGRAFIN SODIUM Approved Use Unknown Launch Date -2.37340803E11
Graves' hyperthyroidism 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3928675	Primary		Approved 8429	ORAGRAFIN SODIUM Approved Use Unknown Launch Date -2.37340803E11

C_max

Value	Dose	Co-administered	Analyte	Population
250 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		IPODIC ACID blood	Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1600 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		IPODIC ACID blood	Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		IPODIC ACID blood	Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	5587-89-3	https://www.alfa-chemistry.com/cas_5587-89-3.htm
Alichem	19120511	http://www.alichem.com/en/products/5587-89-3.html
Ambinter	Amb19844292	http://www.ambinter.com/reference/19844292
Angene	AGN-PC-0SJSYB	http://www.angenechemical.com/productshow/AGN-PC-0SJSYB.html
Aurora Fine Chemicals LLC	A12.862.299	http://online.aurorafinechemicals.com/info?ID=A12.862.299
Aurora Fine Chemicals LLC	K08.695.961	http://online.aurorafinechemicals.com/info?ID=K08.695.961
Aurum Pharmatech LLC	T8924	http://www.Aurumpharmatech.com/Product/ProductDetails/T8924
BLD Pharm	BD434185	http://www.bldpharm.com/products/5587-89-3.html
Chemspace	CSSB00025753969	https://chem-space.com/CSSB00025753969
Smolecule	S590223	https://www.smolecule.com/products/s590223
THE BioTek	bt-432269	https://www.thebiotek.com/product/others/bt-432269
Vitas-M Laboratory	BBL023886	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL023886&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Vitas-M Laboratory	STL069541	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=STL069541&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
eNovation Chemicals	D526883	https://www.enovationchem.com/ProductDetails.asp?ProductID=D526883

PubMed

Title	Date	PubMed
A study of cardiac effects of thyroid hormones: evidence for amelioration of the effects of thyroxine by sodium ipodate.	1984 Jun	6723573
The use of oral radiographic contrast agents in the management of hyperthyroidism.	2001 Jun	11442003
Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis.	2003 Mar	12682620
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.	2007 Jun	17389703

Patents

Sample Use Guides

In Vivo Use Guide

hyperthyroidism: Oragrafin; 0.5 g, orally daily or every other day) for 15-60 day Graves' hyperthyroidism: 500 mg, orally, daily for 23-31 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:17:09 UTC 2023` Edited by `admin` on `Fri Dec 15 16:17:09 UTC 2023`
Record UNII	F604ZKI910
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IPODIC ACID

Common Name

English

IPODATE [MI]

Common Name

English

IOPODIC ACID

Common Name

English

IPODIC ACID [HSDB]

Common Name

English

IPODATE [VANDF]

Common Name

English

Iopodic acid [WHO-DD]

Common Name

English

IOPODIC ACID [MART.]

Common Name

English

IPODATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28500